151 related articles for article (PubMed ID: 34325089)
61. Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study.
Auletta S; Baldoni D; Varani M; Galli F; Hajar IA; Duatti A; Ferro-Flores G; Trampuz A; Signore A
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):37-47. PubMed ID: 28849632
[TBL] [Abstract][Full Text] [Related]
62. Molecular imaging: challenges of bringing imaging of intracellular targets into common clinical use.
Skotland T
Contrast Media Mol Imaging; 2012; 7(1):1-6. PubMed ID: 22344874
[TBL] [Abstract][Full Text] [Related]
63. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.
Vegt E; Wetzels JF; Russel FG; Masereeuw R; Boerman OC; van Eerd JE; Corstens FH; Oyen WJ
J Nucl Med; 2006 Mar; 47(3):432-6. PubMed ID: 16513612
[TBL] [Abstract][Full Text] [Related]
64. Accurate Estimation of Functional Liver Volume Using Gd-EOB-DTPA MRI Compared to MDCT/
Morine Y; Enkhbold C; Imura S; Ikemoto T; Iwahashi S; Saito YU; Yamada S; Utsunomiya T; Shimada M
Anticancer Res; 2017 Oct; 37(10):5693-5700. PubMed ID: 28982888
[TBL] [Abstract][Full Text] [Related]
65. Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of plasminogen activator inhibitor type 2 (PAI-2) forms.
Ranson M; Berghofer P; Vine KL; Greguric I; Shepherd R; Katsifis A
Nucl Med Biol; 2012 Aug; 39(6):833-9. PubMed ID: 22817872
[TBL] [Abstract][Full Text] [Related]
66. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
67. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design.
Hosseinimehr SJ; Tolmachev V; Orlova A
Drug Discov Today; 2012 Nov; 17(21-22):1224-32. PubMed ID: 22781499
[TBL] [Abstract][Full Text] [Related]
68. Advances in the understanding of the nephrotoxicity of radiocontrast media.
Morcos SK; El Nahas AM
Nephron; 1998; 78(3):249-52. PubMed ID: 9546681
[No Abstract] [Full Text] [Related]
69. Single Photon Emission Computed Tomography Tracer.
Pietzsch HJ; Mamat C; Müller C; Schibli R
Recent Results Cancer Res; 2020; 216():227-282. PubMed ID: 32594389
[TBL] [Abstract][Full Text] [Related]
70. The Utility of Unilobar Technetium-99m Macroaggregated Albumin to Predict Pulmonary Toxicity In Bilobar Hepatocellular Carcinoma prior to Yttrium-90 Radioembolization.
Kallini JR; Gabr A; Kulik L; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1453-1456. PubMed ID: 27566430
[No Abstract] [Full Text] [Related]
71. Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists.
Esnault VL
Nephrol Dial Transplant; 2002 Aug; 17(8):1362-4. PubMed ID: 12147778
[No Abstract] [Full Text] [Related]
72. Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs.
Zhang W; Fan W; Ottemann BM; Alshehri S; Garrison JC
J Nucl Med; 2020 Mar; 61(3):443-450. PubMed ID: 31601697
[TBL] [Abstract][Full Text] [Related]
73. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
74. Polymeric radiotracers in nuclear imaging.
Wen X; Cao X; Pasuelo MJ; Wendt R; Li C
Curr Drug Deliv; 2004 Oct; 1(4):377-84. PubMed ID: 16305399
[TBL] [Abstract][Full Text] [Related]
75. MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice.
Chen MH; Chang CH; Chang YJ; Chen LC; Yu CY; Wu YH; Lee WC; Yeh CH; Lin FH; Lee TW; Yang CS; Ting G
Anticancer Res; 2010 Jan; 30(1):65-72. PubMed ID: 20150618
[TBL] [Abstract][Full Text] [Related]
76.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
77. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Van Binnebeek S; Baete K; Vanbilloen B; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Haustermans K; Van Cutsem E; Verbruggen A; Bogaerts K; Verslype C; Deroose CM
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1141-57. PubMed ID: 24668274
[TBL] [Abstract][Full Text] [Related]
78. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
79. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Asif A; Epstein DL; Epstein M
J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304
[TBL] [Abstract][Full Text] [Related]
80. Control of radioactivity pharmacokinetics of 99mTc-HYNIC-labeled polypeptides derivatized with ternary ligand complexes.
Ono M; Arano Y; Mukai T; Saga T; Fujioka Y; Ogawa K; Kawashima H; Konishi J; Saji H
Bioconjug Chem; 2002; 13(3):491-501. PubMed ID: 12009938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
